Lynn Morris to Drug Resistance, Viral
This is a "connection" page, showing publications Lynn Morris has written about Drug Resistance, Viral.
Connection Strength
5,900
-
HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937.
Score: 0,591
-
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. Antimicrob Agents Chemother. 2016 Apr; 60(4):2248-56.
Score: 0,440
-
Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology. 2013 Nov; 446(1-2):66-76.
Score: 0,368
-
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther. 2013; 18(7):915-20.
Score: 0,363
-
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
Score: 0,297
-
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):538-43.
Score: 0,266
-
HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov; 24(11):1449-54.
Score: 0,264
-
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008; 13 Suppl 2:101-7.
Score: 0,249
-
Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS. 2003 Jul 25; 17(11):1698-700.
Score: 0,183
-
Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13. BMC Infect Dis. 2019 Sep 16; 19(Suppl 1):787.
Score: 0,140
-
Low Frequency of Protease Inhibitor Resistance Mutations and Insertions in HIV-1 Subtype C Protease Inhibitor-Naïve Sequences. AIDS Res Hum Retroviruses. 2019 07; 35(7):673-678.
Score: 0,136
-
Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019; 24(3):203-210.
Score: 0,133
-
Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant. Antivir Ther. 2019; 24(5):333-342.
Score: 0,133
-
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017 Nov 01; 72(11):3141-3148.
Score: 0,123
-
Rapid Detection of Common HIV-1 Drug Resistance Mutations by Use of High-Resolution Melting Analysis and Unlabeled Probes. J Clin Microbiol. 2017 01; 55(1):122-133.
Score: 0,116
-
The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. J Virol Methods. 2015 Oct; 223:30-2.
Score: 0,105
-
Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82.
Score: 0,104
-
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015 Apr; 12(4):e1001810.
Score: 0,103
-
Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. J Acquir Immune Defic Syndr. 2015 Apr 01; 68(4):463-71.
Score: 0,103
-
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2015 Feb; 59(2):960-71.
Score: 0,100
-
Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS. 2014 Jul 17; 28(11):1673-8.
Score: 0,098
-
Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. J Infect Dev Ctries. 2014 Jul 14; 8(7):845-52.
Score: 0,098
-
Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods. 2014 Oct; 207:182-7.
Score: 0,098
-
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis. 2014 Jun 15; 209(12):1916-20.
Score: 0,095
-
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):304-8.
Score: 0,081
-
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9.
Score: 0,080
-
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
Score: 0,078
-
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 2009 Apr 27; 23(7):809-16.
Score: 0,068
-
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
Score: 0,067
-
Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study. J Virol. 2008 Nov; 82(22):11476-9.
Score: 0,065
-
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther. 2008; 13 Suppl 2:49-57.
Score: 0,062
-
4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2008 Mar; 82(5):2367-75.
Score: 0,062
-
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):148-53.
Score: 0,058
-
A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol. 2007 Apr; 24(4):1025-31.
Score: 0,058
-
Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1306-12.
Score: 0,058
-
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006 Apr 24; 20(7):995-1002.
Score: 0,055
-
In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. AIDS Res Hum Retroviruses. 2005 Sep; 21(9):776-83.
Score: 0,053
-
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005 Jul 01; 192(1):16-23.
Score: 0,052
-
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. J Virol. 2025 Feb 25; 99(2):e0173024.
Score: 0,051
-
Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses. 2005 Jan; 21(1):103-9.
Score: 0,051
-
Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. AIDS. 2004 Nov 19; 18(17):2327-30.
Score: 0,050
-
Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 01; 209(5):711-20.
Score: 0,023
-
Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infect Genet Evol. 2013 Aug; 18:125-31.
Score: 0,022
-
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
Score: 0,021
-
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 03; 329(5996):1168-74.
Score: 0,019
-
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009 Dec 15; 49(12):1928-35.
Score: 0,018
-
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008 Jul 11; 22(11):1333-43.
Score: 0,016
-
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother. 2006 Feb; 50(2):694-701.
Score: 0,014
-
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005 Apr; 2(4):e112.
Score: 0,013